123 related articles for article (PubMed ID: 34058568)
21. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
22. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.
Guida M; Casamassima A; Monticelli G; Quaranta M; Colucci G
J Transl Med; 2007 Oct; 5():51. PubMed ID: 17953739
[TBL] [Abstract][Full Text] [Related]
23. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
Halefoglu AM; Ozagari AA
Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
[TBL] [Abstract][Full Text] [Related]
24. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
25. [Soluble cytokinin receptors in renal vasculitis and lupus nephritis].
Tesar V; Jirsa M; Masek Z; Bartůnková J; Stejskalová A; Dostál C; Zabka J; Chábová V; Rysavá R
Cas Lek Cesk; 1998 May; 137(9):271-5. PubMed ID: 9650355
[TBL] [Abstract][Full Text] [Related]
26. MCP-1/MCPIP-1 Signaling Modulates the Effects of IL-1β in Renal Cell Carcinoma through ER Stress-Mediated Apoptosis.
Lee CH; Hung PF; Lu SC; Chung HL; Chiang SL; Wu CT; Chou WC; Sun CY
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816951
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
[TBL] [Abstract][Full Text] [Related]
29. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
30. Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Nilsen GH; Beisland C; Straume O
Cancer Treat Res Commun; 2019; 19():100127. PubMed ID: 30913495
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 and TNF alpha production in human renal cell carcinoma.
Gogusev J; Augusti M; Chrétien Y; Droz D
Kidney Int; 1993 Sep; 44(3):585-92. PubMed ID: 8231032
[TBL] [Abstract][Full Text] [Related]
32. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b.
Quan Z; He Y; Luo C; Xia Y; Zhao Y; Liu N; Wu X
Cell Signal; 2017 Apr; 32():48-58. PubMed ID: 28093267
[TBL] [Abstract][Full Text] [Related]
34. Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.
Chang Y; Xu L; An H; Fu Q; Chen L; Lin Z; Xu J
Int J Clin Exp Pathol; 2015; 8(2):1594-603. PubMed ID: 25973044
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma.
Zanjani LS; Madjd Z; Abolhasani M; Rasti A; Fodstad O; Andersson Y; Asgari M
Biomark Med; 2018 Jan; 12(1):45-61. PubMed ID: 29243496
[TBL] [Abstract][Full Text] [Related]
37. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
38. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
[TBL] [Abstract][Full Text] [Related]
39. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
